Ignite Creation Date:
2024-05-06 @ 4:15 PM
Last Modification Date:
2024-10-26 @ 2:06 PM
Study NCT ID:
NCT04920617
Status:
RECRUITING
Last Update Posted:
2023-04-07
First Post:
2021-05-28
Brief Title:
DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide in Subjects With RelapsedRefractory Diffuse Large B-Cell Lymphoma
Sponsor:
ImmunoVaccine Technologies Inc IMV Inc
Organization:
ImmunoVaccine Technologies Inc IMV Inc